{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:28:45Z","timestamp":1791905325318,"version":"4.3.4"},"reference-count":121,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1097\/01.ajp.0000210902.67849.e6","type":"journal-article","created":{"date-parts":[[2006,8,21]],"date-time":"2006-08-21T08:01:31Z","timestamp":1156147291000},"page":"587-600","source":"Crossref","is-referenced-by-count":79,"title":["Similarities and Differences in Tumor Growth, Skeletal Remodeling and Pain in an Osteolytic and Osteoblastic Model of Bone Cancer"],"prefix":"10.1097","volume":"22","author":[{"given":"Kyle G.","family":"Halvorson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly A.","family":"Sevcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Rosol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Mantyh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-1-20210204","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"R2-1-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(96)03267-8","article-title":"Malignant bone pain: pathophysiology and treatment","volume":"69","author":"Mercadante","year":"1997","journal-title":"Pain"},{"key":"R3-1-20210204","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0305-7372(98)90005-6","article-title":"Breakthrough pain in cancer patients: pathophysiology and treatment","volume":"24","author":"Mercadante","year":"1998","journal-title":"Cancer Treat Rev"},{"key":"R4-1-20210204","first-page":"8","article-title":"New strategies in opioid therapy for cancer pain","volume":"9","author":"Cherny","year":"2000","journal-title":"J Oncol Manag"},{"key":"R5-1-20210204","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1054\/bjoc.2001.1680","article-title":"Morphine and alternative opioids in cancer pain: the Eapc recommendations","volume":"84","author":"Hanks","year":"2001","journal-title":"Br J Cancer"},{"key":"R6-1-20210204","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(99)01310-0","article-title":"Management of cancer pain","volume":"353","author":"Portenoy","year":"1999","journal-title":"Lancet"},{"key":"R7-1-20210204","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00001813-199504003-00002","article-title":"Misconceptions and controversies regarding the use of opioids in cancer pain","volume":"6","author":"Foley","year":"1995","journal-title":"Anticancer Drugs"},{"key":"R8-1-20210204","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0885-3924(98)00103-1","article-title":"Documentation of severe pain, opioid doses, and opioid-related side effects in outpatients with cancer: a retrospective study","volume":"17","author":"Weber","year":"1999","journal-title":"J Pain Symptom Manage"},{"key":"R9-1-20210204","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective Cox-2 inhibitors","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"R10-1-20210204","first-page":"332","article-title":"Cox-2 selective inhibitors cardiac toxicity: getting to the heart of the matter","volume":"7","author":"Davies","year":"2004","journal-title":"J Pharm Pharm Sci"},{"key":"R11-1-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(98)00118-3","article-title":"Problems of long-term spinal opioid treatment in advanced cancer patients","volume":"79","author":"Mercadante","year":"1999","journal-title":"Pain"},{"key":"R12-1-20210204","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/canjclin.55.1.10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R13-1-20210204","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1572::AID-CNCR7>3.0.CO;2-M","article-title":"Parathyroid hormone-related protein and bone metastases","volume":"80","author":"Guise","year":"1997","journal-title":"Cancer"},{"key":"R14-1-20210204","doi-asserted-by":"crossref","first-page":"9426","DOI":"10.1158\/0008-5472.CAN-05-0826","article-title":"A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone","volume":"65","author":"Halvorson","year":"2005","journal-title":"Cancer Res"},{"key":"R15-1-20210204","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0306-4522(00)00110-X","article-title":"Murine models of inflammatory, neuropathic and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons","volume":"98","author":"Honore","year":"2000","journal-title":"Neuroscience"},{"key":"R16-1-20210204","first-page":"7343","article-title":"Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2","volume":"62","author":"Sabino","year":"2002","journal-title":"Cancer Res"},{"key":"R17-1-20210204","doi-asserted-by":"crossref","first-page":"10886","DOI":"10.1523\/JNEUROSCI.19-24-10886.1999","article-title":"Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain","volume":"19","author":"Schwei","year":"1999","journal-title":"J Neurosci"},{"key":"R18-1-20210204","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/S8756-3282(09)80011-2","article-title":"Metastatic bone disease: clinical and therapeutic aspects","volume":"13","author":"Body","year":"1992","journal-title":"Bone"},{"key":"R19-1-20210204","first-page":"4038","article-title":"Osteoprotegerin diminishes advanced bone cancer pain","volume":"61","author":"Luger","year":"2001","journal-title":"Cancer Res"},{"key":"R20-1-20210204","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.expneurol.2004.11.028","article-title":"Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain","volume":"193","author":"Peters","year":"2005","journal-title":"Exp Neurol"},{"key":"R21-1-20210204","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1677\/erc.0.0060333","article-title":"Factors regulating the growth of metastatic cancer in bone","volume":"6","author":"Boyce","year":"1999","journal-title":"Endocr Relat Cancer"},{"key":"R22-1-20210204","article-title":"The Human Brain: An Introduction to its Functional Anatomy","author":"Nolte","year":"2002"},{"key":"R23-1-20210204","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/j.1469-7793.1998.857ba.x","article-title":"Association of somatic action potential shape with sensory receptive properties in Guinea-Pig dorsal root ganglion neurones","volume":"513","author":"Djouhri","year":"1998","journal-title":"J Physiol"},{"key":"R24-1-20210204","first-page":"472","article-title":"Principles of Neural Science","author":"Basbaum","year":"2000"},{"key":"R25-1-20210204","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35093019","article-title":"Molecular mechanisms of nociception [review]","volume":"413","author":"Julius","year":"2001","journal-title":"Nature"},{"key":"R26-1-20210204","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1523\/JNEUROSCI.20-04-01495.2000","article-title":"Developmental changes in the transmitter properties of sympathetic neurons that innervate the periosteum","volume":"20","author":"Asmus","year":"2000","journal-title":"J Neurosci"},{"key":"R27-1-20210204","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00186871","article-title":"Neuroendocrine peptides in bone","volume":"15","author":"Bjurholm","year":"1991","journal-title":"Int Orthop"},{"key":"R28-1-20210204","first-page":"1252","article-title":"Innervation of bone from healthy and arthritic rats by substance P and calcitonin gene related peptide containing sensory fibers","volume":"19","author":"Hukkanen","year":"1992","journal-title":"J Rheumatol"},{"key":"R29-1-20210204","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0196-9781(88)90023-X","article-title":"Substance P-and CGRP-immunoreactive nerves in bone","volume":"9","author":"Bjurholm","year":"1988","journal-title":"Peptides"},{"key":"R30-1-20210204","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-1838(88)90016-1","article-title":"Neuropeptide Y-, tyrosine hydroxylase- and vasoactive intestinal polypeptide-immunoreactive nerves in bone and surrounding tissues","volume":"25","author":"Bjurholm","year":"1988","journal-title":"J Auton Nerv Syst"},{"key":"R31-1-20210204","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0065-1281(96)80013-4","article-title":"Noradrenergic and peptidergic innervation of the mouse femur bone marrow","volume":"98","author":"Tabarowski","year":"1996","journal-title":"Acta Histochem"},{"key":"R32-1-20210204","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1006\/mcne.1999.0814","article-title":"Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury","volume":"15","author":"Tsujino","year":"2000","journal-title":"Mol Cell Neurosci"},{"key":"R33-1-20210204","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/74999","article-title":"Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemcial reorganization of the spinal cord","volume":"6","author":"Honore","year":"2000","journal-title":"Nat Med"},{"key":"R34-1-20210204","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.pain.2005.02.022","article-title":"Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization","volume":"115","author":"Sevcik","year":"2005","journal-title":"Pain"},{"key":"R35-1-20210204","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1523\/JNEUROSCI.3815-04.2005","article-title":"Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain","volume":"25","author":"Ghilardi","year":"2005","journal-title":"J Neurosci"},{"key":"R36-1-20210204","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0304-3959(02)00296-8","article-title":"Contribution of injured and uninjured dorsal root ganglion neurons to pain behavior and the changes in gene expression following chronic constriction injury of the sciatic nerve in rats","volume":"101","author":"Obata","year":"2003","journal-title":"Pain"},{"key":"R37-1-20210204","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/74999","article-title":"Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord","volume":"6","author":"Honore","year":"2000","journal-title":"Nat Med"},{"key":"R38-1-20210204","first-page":"4038","article-title":"Osteoprotegerin diminishes advanced bone cancer pain","volume":"61","author":"Luger","year":"2001","journal-title":"Cancer Res"},{"key":"R39-1-20210204","first-page":"289","article-title":"Biology and Physiology of the Osteoclast","author":"Delaisse","year":"1992"},{"key":"R40-1-20210204","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00003086-200004000-00013","article-title":"Review of cellular mechanisms of tumor osteolysis","volume":"373","author":"Clohisy","year":"2000","journal-title":"Clin Orthop Relat Res"},{"key":"R41-1-20210204","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"R42-1-20210204","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0304-3959(98)00135-3","article-title":"The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials","volume":"78","author":"Fulfaro","year":"1998","journal-title":"Pain"},{"key":"R43-1-20210204","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/(SICI)1097-0142(20000101)88:1<6::AID-CNCR3>3.0.CO;2-D","article-title":"Oral bisphosphonates: a review of clinical use in patients with bone metastases","volume":"88","author":"Major","year":"2000","journal-title":"Cancer"},{"key":"R44-1-20210204","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"R45-1-20210204","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00002512-199915040-00004","article-title":"New bisphosphonates in the treatment of bone diseases","volume":"15","author":"Gatti","year":"1999","journal-title":"Drugs Aging"},{"key":"R46-1-20210204","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1126\/science.289.5484.1508","article-title":"Therapeutic approaches to bone diseases","volume":"289","author":"Rodan","year":"2000","journal-title":"Science"},{"key":"R47-1-20210204","first-page":"4418","article-title":"The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases","volume":"61","author":"Hiraga","year":"2001","journal-title":"Cancer Res"},{"key":"R48-1-20210204","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1002\/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U","article-title":"Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma","volume":"88","author":"Yoneda","year":"2000","journal-title":"Cancer"},{"key":"R49-1-20210204","first-page":"3551","article-title":"Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice","volume":"55","author":"Sasaki","year":"1995","journal-title":"Cancer Res"},{"key":"R50-1-20210204","first-page":"265","article-title":"Principles of Bone Biology","volume":"1","author":"Horton","year":"2002"},{"key":"R51-1-20210204","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pain.2004.06.015","article-title":"Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis","volume":"111","author":"Sevcik","year":"2004","journal-title":"Pain"},{"key":"R52-1-20210204","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin -- a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"R53-1-20210204","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"R54-1-20210204","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to Trance\/Rankl","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R55-1-20210204","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0079-6123(00)29003-1","article-title":"Chemical mediators of pain due to tissue damage and ischemia","volume":"129","author":"Sutherland","year":"2000","journal-title":"Prog Brain Res"},{"key":"R56-1-20210204","doi-asserted-by":"crossref","first-page":"441","DOI":"10.7326\/0003-4819-140-8-200404200-00010","article-title":"Pain: moving from symptom control toward mechanism-specific pharmacologic management","volume":"140","author":"Woolf","year":"2004","journal-title":"Ann Intern Med"},{"key":"R57-1-20210204","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/00001756-199804200-00028","article-title":"An Acid Sensing Ion Channel (ASIC) localizes to small primary afferent neurons in rats","volume":"9","author":"Olson","year":"1998","journal-title":"Neuroreport"},{"key":"R58-1-20210204","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/39807","article-title":"The capsaicin receptor: a heat-activated ion channel in the pain pathway","volume":"389","author":"Caterina","year":"1997","journal-title":"Nature"},{"key":"R59-1-20210204","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0896-6273(00)80564-4","article-title":"The cloned capsaicin receptor integrates multiple pain-producing stimuli","volume":"21","author":"Tominaga","year":"1998","journal-title":"Neuron"},{"key":"R60-1-20210204","doi-asserted-by":"crossref","first-page":"28819","DOI":"10.1074\/jbc.272.46.28819","article-title":"The acid-sensitive ionic channel subunit asic and the mammalian degenerin MDEG form a heteromultimeric H+-gated Na+ channel with novel properties","volume":"272","author":"Bassilana","year":"1997","journal-title":"J Biol Chem"},{"key":"R61-1-20210204","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/bjc.1991.326","article-title":"Are cancer cells acidic?","volume":"64","author":"Griffiths","year":"1991","journal-title":"Br J Cancer"},{"key":"R62-1-20210204","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2174\/0929867306666220320221415","article-title":"Modulating apoptosis: current applications and prospects for future drug development","volume":"6","author":"Deigner","year":"1999","journal-title":"Curr Med Chem"},{"key":"R63-1-20210204","first-page":"113","article-title":"Bone Diseases","author":"Claus-Peter","year":"2000"},{"key":"R65-1-20210204","first-page":"305","article-title":"Tumor Bone Disease and Osteoporsis in Cancer Patients","author":"Rubert Cynthia","year":"2000"},{"key":"R66-1-20210204","first-page":"65","article-title":"Bone Diseases","author":"Claus-Peter","year":"2000"},{"key":"R67-1-20210204","first-page":"207","article-title":"Bone Diseases","author":"Claus-Peter","year":"2000"},{"key":"R68-1-20210204","first-page":"71","article-title":"Tumor Bone Diseases and Osteoporosis in Cancer Patients","author":"Goltzman DaR","year":"2000"},{"key":"R69-1-20210204","first-page":"31","article-title":"Bone Diseases","author":"Claus-Peter","year":"2000"},{"key":"R70-1-20210204","first-page":"85","article-title":"Tumor Bone Diseases and Osteoporosis in Cancer Patients","author":"Rubens","year":"2000"},{"key":"R71-1-20210204","first-page":"64","article-title":"Diagnosis of skeletal metastases and assessment of response to treatment","volume":"312","author":"Galasko","year":"1995","journal-title":"Clin Orthop Relat Res"},{"key":"R72-1-20210204","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1200\/JCO.1991.9.3.509","article-title":"Bone metastases: pathophysiology and management policy","volume":"9","author":"Nielsen","year":"1991","journal-title":"J Clin Oncol"},{"key":"R73-1-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(00)00490-5","article-title":"The role of neuroinflammation and neuroimmune activation in persistent pain","volume":"90","author":"DeLeo","year":"2001","journal-title":"Pain"},{"key":"R74-1-20210204","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0304-3959(95)00186-7","article-title":"Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states","volume":"63","author":"Watkins","year":"1995","journal-title":"Pain"},{"key":"R75-1-20210204","doi-asserted-by":"crossref","first-page":"7710","DOI":"10.1073\/pnas.96.14.7710","article-title":"Implications of immune-to-brain communication for sickness and pain","volume":"96","author":"Watkins","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"R76-1-20210204","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0022-5347(05)67497-6","article-title":"IL-1beta and TNF-alpha in prostatic secretions are indicators in the evaluation of men with chronic prostatitis","volume":"164","author":"Nadler","year":"2000","journal-title":"J Urol"},{"key":"R77-1-20210204","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1526-4637.2001.002001024.x","article-title":"Endothelin-1 and metastatic cancer pain","volume":"2","author":"Davar","year":"2001","journal-title":"Pain Med"},{"key":"R78-1-20210204","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1046\/j.1464-410X.2000.00063.x","article-title":"The role of endothelin-1 and endothelin receptor antagonists in prostate cancer","volume":"85","author":"Nelson","year":"2000","journal-title":"BJU Int"},{"key":"R79-1-20210204","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1523\/JNEUROSCI.20-16-06289.2000","article-title":"Involvement of the proinflammatory cytokines tumor necrosis factor-alpha, IL-1 beta, and IL-6 but not IL-8 in the development of heat hyperalgesia: effects on heat-evoked calcitonin gene-related peptide release from rat skin","volume":"20","author":"Opree","year":"2000","journal-title":"J Neurosci"},{"key":"R80-1-20210204","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/0006-8993(95)00715-3","article-title":"Mechanisms of tumor necrosis factor-alpha (TNF-alpha) hyperalgesia","volume":"692","author":"Watkins","year":"1995","journal-title":"Brain Res"},{"key":"R81-1-20210204","first-page":"1030","article-title":"Role of epidermal growth factor in carcinogenesis","volume":"46","author":"Stoscheck","year":"1986","journal-title":"Cancer Res"},{"key":"R82-1-20210204","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1200\/JCO.2001.19.4.1207","article-title":"Clinical implications of circulating angiogenic factors in cancer patients","volume":"19","author":"Poon","year":"2001","journal-title":"J Clin Oncol"},{"key":"R83-1-20210204","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/1097-0029(20010215)52:4<450::AID-JEMT1030>3.0.CO;2-O","article-title":"TGF-beta and colorectal carcinogenesis","volume":"52","author":"Roman","year":"2001","journal-title":"Microsc Res Tech"},{"key":"R84-1-20210204","first-page":"217","article-title":"Platelet-derived growth factor in human malignancy","volume":"3","author":"Silver","year":"1992","journal-title":"Biofactors"},{"key":"R85-1-20210204","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0889-8529(18)30258-5","article-title":"Tumor secretion of growth factors","volume":"20","author":"Daughaday","year":"1991","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R86-1-20210204","first-page":"169","article-title":"Growth factors and their receptors in metastasis","volume":"2","author":"Radinsky","year":"1991","journal-title":"Semin Cancer Biol"},{"key":"R87-1-20210204","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0093-7754(03)00353-1","article-title":"Endothelin receptor antagonists in the treatment of prostate cancer","volume":"30","author":"Lassiter","year":"2003","journal-title":"Semin Oncol"},{"key":"R88-1-20210204","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.neuroscience.2004.04.027","article-title":"Endothelin and the tumorigenic component of bone cancer pain","volume":"126","author":"Peters","year":"2004","journal-title":"Neuroscience"},{"key":"R89-1-20210204","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/sj.neo.7900166","article-title":"Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma","volume":"3","author":"Shappell","year":"2001","journal-title":"Neoplasia"},{"key":"R90-1-20210204","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ijc.1397","article-title":"Increased cyclooxygenase-2 (Cox-2) expression and activity in a murine model of metastatic breast cancer","volume":"93","author":"Kundu","year":"2001","journal-title":"Int J Cancer"},{"key":"R91-1-20210204","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1097-0142(20010515)91:10<1876::AID-CNCR1209>3.0.CO;2-H","article-title":"Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma","volume":"91","author":"Ohno","year":"2001","journal-title":"Cancer"},{"key":"R92-1-20210204","first-page":"4356","article-title":"et al Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs","volume":"59","author":"Molina","year":"1999","journal-title":"Cancer Res"},{"key":"R93-1-20210204","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1053\/gast.1996.v110.pm8613017","article-title":"Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors","volume":"110","author":"Dubois","year":"1996","journal-title":"Gastroenterology"},{"key":"R94-1-20210204","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0079-6123(08)61801-4","article-title":"Prostaglandin-induced neuropeptide release from spinal cord","volume":"104","author":"Vasko","year":"1995","journal-title":"Prog Brain Res"},{"key":"R95-1-20210204","article-title":"Principles of Bone Biology","author":"Pilbeam","year":"London: Academic Press; 2002"},{"key":"R96-1-20210204","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/35094017","article-title":"Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2","volume":"1","author":"Gupta","year":"2001","journal-title":"Nature Rev Cancer"},{"key":"R97-1-20210204","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues [review]","volume":"94","author":"Thun","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"R98-1-20210204","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/nm0901-1048","article-title":"Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice","volume":"7","author":"Sonoshita","year":"2001","journal-title":"Nat Med"},{"key":"R99-1-20210204","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI119400","article-title":"Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2","volume":"99","author":"Sheng","year":"1997","journal-title":"J Clin Invest"},{"key":"R100-1-20210204","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1172\/JCI9621","article-title":"Host cyclooxygenase-2 modulates carcinoma growth","volume":"105","author":"Williams","year":"2000","journal-title":"J Clin Invest"},{"key":"R101-1-20210204","first-page":"1306","article-title":"Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors","volume":"60","author":"Masferrer","year":"2000","journal-title":"Cancer Res"},{"key":"R102-1-20210204","first-page":"2101","article-title":"Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor","volume":"60","author":"Harris","year":"2000","journal-title":"Cancer Res"},{"key":"R103-1-20210204","first-page":"293","article-title":"Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis","volume":"60","author":"Reddy","year":"2000","journal-title":"Cancer Res"},{"key":"R104-1-20210204","first-page":"6131","article-title":"Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1\/2 inhibitor","volume":"61","author":"Lal","year":"2001","journal-title":"Cancer Res"},{"key":"R105-1-20210204","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2002.08.028","article-title":"Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. [Erratum Appears in J Clin Oncol. 2003 Jun 15;21(12):2449]","volume":"20","author":"Carducci","year":"2002","journal-title":"J Clin Oncol"},{"key":"R106-1-20210204","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/nm0995-944","article-title":"Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate","volume":"1","author":"Nelson","year":"1995","journal-title":"Nat Med"},{"key":"R107-1-20210204","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1523\/JNEUROSCI.21-03-00999.2001","article-title":"Expression and localization of endothelin receptors: implication for the involvement of peripheral glia in nociception","volume":"21","author":"Pomonis","year":"2001","journal-title":"J Neurosci"},{"key":"R108-1-20210204","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1097\/00001756-199807130-00025","article-title":"Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve","volume":"9","author":"Davar","year":"1998","journal-title":"Neuroreport"},{"key":"R109-1-20210204","first-page":"306","article-title":"Angiogenesis in cancer: the role of endothelin-1","volume":"81","author":"Dawas","year":"1999","journal-title":"Ann R Coll Surg Engl"},{"key":"R110-1-20210204","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0748-7983(98)80128-5","article-title":"Endothelin-1 and tumour development","volume":"24","author":"Asham","year":"1998","journal-title":"Eur J Surg Oncol"},{"key":"R111-1-20210204","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0014-2999(01)01318-8","article-title":"Kinin receptors in pain and inflammation","volume":"429","author":"Couture","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"R112-1-20210204","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0304-3959(03)00141-6","article-title":"Regulation and function of spinal and peripheral neuronal B1 bradykinin receptors in inflammatory mechanical hyperalgesia","volume":"104","author":"Fox","year":"2003","journal-title":"Pain"},{"key":"R113-1-20210204","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jpain.2005.06.010","article-title":"Analgesic efficacy of bradykinin B1 antagonists in a murine bone cancer pain model","volume":"6","author":"Sevcik","year":"2005","journal-title":"J Pain"},{"key":"R114-1-20210204","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0304-3959(96)03060-6","article-title":"Characteristics of nerve growth factor induced hyperalgesia in adult rats: dependence on enhanced bradykinin-1 receptor activity but not neurokinin-1 receptor activation","volume":"66","author":"Rueff","year":"1996","journal-title":"Pain"},{"key":"R115-1-20210204","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1523\/JNEUROSCI.10-06-02018.1990","article-title":"Influence of nerve growth factor on neurofilament gene expression in mature primary sensory neurons","volume":"10","author":"Verge","year":"1990","journal-title":"J Neurosci"},{"key":"R116-1-20210204","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1111\/j.1460-9568.2004.03241.x","article-title":"NGF and GDNF ameliorate the increase in ATF3 expression which occurs in dorsal root ganglion cells in response to peripheral nerve injury","volume":"19","author":"Averill","year":"2004","journal-title":"Eur J Neurosci"},{"key":"R117-1-20210204","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0306-4522(92)90237-V","article-title":"Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in Vivo","volume":"49","author":"Donnerer","year":"1992","journal-title":"Neuroscience"},{"key":"R118-1-20210204","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0006-8993(99)02216-7","article-title":"A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain","volume":"854","author":"Gould","year":"2000","journal-title":"Brain Res"},{"key":"R119-1-20210204","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0896-6273(02)00908-X","article-title":"P38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia","volume":"36","author":"Ji","year":"2002","journal-title":"Neuron"},{"key":"R120-1-20210204","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1046\/j.1471-4159.2001.00288.x","article-title":"Nerve growth factor induces P2x(3) expression in sensory neurons","volume":"77","author":"Ramer","year":"2001","journal-title":"J Neurochem"},{"key":"R121-1-20210204","doi-asserted-by":"crossref","first-page":"48907","DOI":"10.1074\/jbc.M309468200","article-title":"How nerve growth factor drives physiological and inflammatory expressions of acid-sensing ion channel 3 in sensory neurons","volume":"278","author":"Mamet","year":"2003","journal-title":"J Biol Chem"},{"key":"R122-1-20210204","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1083\/jcb.104.6.1623","article-title":"Changes of nerve growth factor synthesis in nonneuronal cells in response to sciatic nerve transection","volume":"104","author":"Heumann","year":"1987","journal-title":"J Cell Biol"}],"container-title":["The Clinical Journal of Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00132586-200606000-00034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T15:45:52Z","timestamp":1683560752000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002508-200609000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":121,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.ajp.0000210902.67849.e6","relation":{},"ISSN":["0749-8047"],"issn-type":[{"value":"0749-8047","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}